



Working to improve your health

31 July 2026

Results of AFT Pharmaceuticals Limited's 2026 Annual Shareholders' Meeting

At AFT Pharmaceuticals Limited's (NZX: AFT / ASX: AFP) 2026 Annual Shareholders' Meeting held in Auckland, New Zealand today, shareholders were asked to vote on two resolutions, which were supported by the Board.

As required by NZX Listing Rule 6.1, all voting was conducted by a poll.

The resolutions passed by shareholders were:

1. That Marree Atkinson be re-elected as director of the company.
2. That the directors be authorised to fix the fees and expenses of the auditor for the ensuing year.

Details of the total number of votes cast in person or by a proxy holder are:

Resolution	For	Against	Abstain
That Marree Atkinson be re-elected as a director of the Company.	90,632,137 (99.98%)	20,084 (0.02%)	5,552
That the directors be authorised to fix the fees and expenses of the auditor for the ensuing year.	90,626,491 (99.97%)	25,943 (0.03%)	5,339

Authority for this announcement	
Name of person authorised to make this announcement	Stuart Houlston
Contact person for this announcement	Stuart Houlston Chief Financial Officer
Contact phone number	+64 21 920 653
Contact email address	stuart.houlston@aftpharm.com
Date of release through MAP	31/07/2026

For more information:

Investors

Dr Hartley Atkinson
Managing Director
AFT Pharmaceuticals
Tel: +64 9488 0232

Media

Richard Inder
The Project
Tel: +64 21 645 643

About AFT Pharmaceuticals

AFT is a growing New Zealand based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription, and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs¹. Our business model is to develop and in-license products for in our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland, and UK, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com.